| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-01-11 | Scancell (UK) ImmunID (France) | ImmunTraCkeR® and DNA ImmunoBody® vaccine SCIB1 | metastatic melanoma | R&D |
Cancer - Oncology | Milestone |
| 2016-01-11 | Incyte (USA - DE) AstraZeneca (UK) | INCB39110 and Tagrisso® (osimertinib) | EGFR mutation-positive non-small cell lung cancer (NSCLC) | clinical research | Cancer - Oncology | Clinical research agreement |
| 2016-01-11 | AstraZeneca (UK) Moderna Therapeutics (USA) | messenger RNA (mRNA) therapeutic candidates | R&D development commercialisation |
Cancer - Oncology | R&D agreement | |
| 2016-01-11 | Medivation (USA - CA) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-01-11 | Celgene (USA - NJ) | nomination | Cancer - Oncology | Nomination | ||
| 2016-01-11 | Ferring Pharmaceuticals (Switzerland) Targeted Immuno Therapies (Sweden) | cell therapy | inflammatory bowel Diseases, including Ulcerative Colitis, Crohn’s Disease, unclassified colitis as well as microscopic colitis) | licensing collaboration |
Gastrointestinal diseases - Digestive diseases | Licensing agreement |
| 2016-01-11 | Serodus (Norway) | type 2 diabetes | nomination |
Metabolic diseases | Nomination | |
| 2016-01-11 | Novartis (Switzerland) Surface Oncology (USA - MA) | immunotherapeutics targeting the tumor microenvironment and the interface of innate and adaptive immunity | collaboration | Cancer - Oncology | Collaboration agreement | |
| 2016-01-11 | Synpromics (UK) Cell and Gene Therapy Catapult (UK) | large scale viral vector manufacturing platform | development | Technology - Services | Development agreement | |
| 2016-01-11 | Roslin Cells (UK) | Roslin Cell Therapies, Roslin Cell Sciences | establishment of a new subsidiary in Europe | Technology - Services | Establishment of a new subsidiary in the EU | |
| 2016-01-10 | Innate Pharma (France) Orega Biotech (France) | anti-CD39 checkpoint inhibitors | licensing |
Cancer - Oncology | Licensing agreement | |
| 2016-01-10 | Freeline Therapeutics (UK) | nomination |
Hematologic diseases - Genetic diseases - Rare diseases | Nomination | ||
| 2016-01-10 | Illumina (USA - CA) GRAIL (USA - CA) | pan-cancer screening test by directly measuring circulating nucleic acids in blood | establishment of a new subsidiary in the US |
Cancer - Oncology - Diagnostic | Establishment of a new subsidiary in the US | |
| 2016-01-09 | Y-mAbs Therapeutics (USA - NY) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-01-08 | Tiziana Life Sciences (UK) Cardiff University (UK) | Bcl-3 inhibitors, OH14 | licensing |
Cancer - Oncology | Licensing agreement | |
| 2016-01-08 | Innoviva previously known as Theravance (USA - CA) | name change |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Establishment of a new subsidiary in the EU | ||
| 2016-01-08 | WuXi AppTec (China) | construction of new premises |
Technology - Services | Construction of new premises | ||
| 2016-01-08 | Moderna Therapeutics (USA - MA) Pharmaceutical Product Development (PPD) (USA - NC) | development |
Technology - Services | Development agreement | ||
| 2016-01-08 | Momenta Pharmaceuticals (USA - MA) Mylan (USA - | six of Momenta's current biosimilar candidates, including Momenta's biosimilar candidate Orencia® (abatacept). | development collaboration production manufacturing commercialisation |
Development agreement | ||
| 2016-01-08 | Takeda Pharmaceutical (Japan) NsGene (Denmark) | encapsulated cell therapies delivering recombinant Glial Cell Line-Derived Neurotrophic Factor (GDNF) | Parkinson's disease | R&D |
Neurodegenerative diseases - CNS diseases - Neurological diseases - Regenerative medicine | R&D agreement |
